前列腺癌MRI局部范围与前列腺切除术后组织病理学比较:与长期肿瘤学结局的关联
该项符合HIPAA的回顾性分析纳入2160例前列腺切除术前接受T2加权MRI的患者,评估MRI对前列腺癌局部范围(前列腺外侵犯和精囊侵犯)的判断与病理分期不一致时与术后复发和生存的关系。结果显示,MRI所示肿瘤局部范围与术后肿瘤学结局相关,且独立于病理肿瘤分期。
要点
- MRI判断为器官局限而病理为pT3者,15年BCR风险30%,低于MRI与病理一致前列腺外侵犯者的68%。
- 病理pT2而MRI判断为前列腺外侵犯者,BCR风险27%,高于MRI与病理一致器官局限者的10%。
- 多因素分析中,MRI肿瘤范围(HR范围4.1-5.2)与病理评估(HR范围3.6-6.7)均与BCR、转移和前列腺癌特异性死亡风险相关。
核心结论
- MRI所示前列腺癌局部范围与前列腺切除术后肿瘤学结局相关,且独立于病理肿瘤分期。
- 作者认为这可能为如何将MRI整合入临床分期算法提供信息。
研究设计与样本
- 符合《健康保险可携性与责任法案》(HIPAA)的回顾性分析,分析2001年1月至2006年前列腺切除术前T2加权前列腺MRI。
- 共评估2160例患者,中位年龄60岁(四分位距55-64岁)。
- 前列腺外侵犯和精囊侵犯采用五点Likert量表评估,评分4分或以上归类为阳性。
- 以根治性前列腺切除术后组织病理学为参考标准,采用Kaplan-Meier法和Cox模型估计生化复发(BCR)、转移和前列腺癌特异性死亡率。
关键影像表现/征象
- MRI判断为器官局限而病理为前列腺外侵犯(pT3)者,15年生化复发风险30%(95%CI:22,40),MRI与病理一致前列腺外侵犯者为68%(95%CI:60,75)。
- 上述两组15年转移风险分别为14%(95%CI:8.4,24)与32%(95%CI:26,39)。
- 上述两组15年前列腺癌特异性死亡风险分别为3%(95%CI:1,6)与15%(95%CI:9.5,23),所有比较P < .001。
- 病理为器官局限(pT2)而MRI判断为前列腺外侵犯者,BCR风险27%(95%CI:19,37),MRI与病理一致器官局限者为10%(95%CI:8,14),P < .001。
- 上述pT2亚组中,MRI判断前列腺外侵犯者转移风险19%(95%CI:6,48),一致器官局限者为3%(95%CI:1,6),P < .001;前列腺癌特异性死亡风险2%(95%CI:1,9)与1%(95%CI:0,5),P = .009。
诊断标准与关键数值
- 前列腺外侵犯和精囊侵犯采用五点Likert量表评估,评分4分或以上归类为阳性。
- 病理前列腺外侵犯(pT3)者683/2160(32%),其中MRI判断器官局限者384/683(56%)。
- 病理器官局限(pT2)者1477/2160(68%),其中MRI判断前列腺外侵犯者102/1477(7%)。
- 多因素分析中,MRI肿瘤范围与BCR、转移和前列腺癌特异性死亡风险相关(HR范围4.1-5.2,P < .001)。
- 多因素分析中,组织病理学评估与BCR、转移和前列腺癌特异性死亡风险相关(HR范围3.6-6.7,P < .001)。
临床应用与阅片要点
- 阅片时按五点Likert量表评估前列腺外侵犯和精囊侵犯,评分4分或以上判为阳性。
- 报告MRI所示肿瘤局部范围时需注意,其与术后肿瘤学结局相关且独立于病理分期。
- 作者认为该结果可能为如何将MRI整合入临床分期算法提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background It is unknown how the imperfect accuracy of MRI for local staging of prostate cancer relates to oncologic outcomes. Purpose To analyze how staging discordances between MRI and histopathologic evaluation relate to recurrence and survival after radical prostatectomy. Materials and Methods Health Insurance Portability and Accountability Act-compliant retrospective analysis of preprostatectomy T2-weighted prostate MRI (January 2001 to December 2006). Extraprostatic extension and seminal vesicle invasion were assessed by using five-point Likert scales; scores of 4 or higher were classified as positive. Biochemical recurrence (BCR), metastases, and prostate cancer-specific mortality rates were estimated with Kaplan-Meier and Cox models. Results A total of 2160 patients (median age, 60 years; interquartile range, 55-64 years) were evaluated. Among patients with histopathologic extraprostatic (pT3) disease (683 of 2160; 32%), those with organ-confined disease at MRI (384 of 683; 56%) experienced better outcomes than those with concordant extraprostatic disease at MRI and pathologic analysis: 15-year risk for BCR, 30% (95% CI: 22, 40) versus 68% (95% CI: 60, 75); risk for metastases, 14% (95% CI: 8.4, 24) versus 32% (95% CI: 26, 39); risk for prostate cancer-specific mortality, 3% (95% CI: 1, 6) versus 15% (95% CI: 9.5, 23) (P < .001 for all comparisons). Among patients with histopathologic organ-confined disease (pT2) (1477 of 2160; 68%), those with extraprostatic disease at MRI (102 of 1477; 7%) were at higher risk for BCR (27% [95% CI: 19, 37] vs 10% [95% CI: 8, 14]; P < .001), metastases (19% [95% CI: 6, 48] vs 3% [95% CI: 1, 6]; P < .001), and prostate cancer-specific mortality (2% [95% CI: 1, 9] vs 1% [95% CI: 0, 5]; P = .009) than those with concordant organ-confined disease at MRI and pathologic analysis. At multivariable analyses, tumor extent at MRI (hazard ratio range, 4.1-5.2) and histopathologic evaluation (hazard ratio range, 3.6-6.7) was associated with the risk for BCR, metastases, and prostate cancer-specific mortality (P < .001 for all analyses). Conclusion The local extent of prostate cancer at MRI is associated with oncologic outcomes after prostatectomy, independent of pathologic tumor stage. This might inform a strategy on how to integrate MRI into a clinical staging algorithm. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Gottlieb in this issue.
引用
- Wibmer, Nikolovski, Chaim, et al. Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. Radiology. 2021. PMID: 34931855. doi:10.1148/radiol.210875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。